[1] Our World in Data.COVID-19 data explorer[EB/OL].[2022-11-22].https://ourworldindata.org/coronavirus#explore-the-global-situation.
[2] Arya R, Kumari S, Pandey B, et al.Structural insights into SARS-CoV-2 proteins[J].Journal of Molecular Biology, 2021, 433(2):166725.
[3] Kirtipal N, Bharadwaj S, Kang S G.From SARS to SARSCoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses[J].Infection Genetics and Evolution, 2020, 85:104502.
[4] Kadam S B, Sukhramani G S, Bishnoi P, et al.SARSCoV-2, the pandemic coronavirus:Molecular and structural insights[J].Journal of Basic Microbiology, 2021, 61(3):180-202.
[5] Giovanetti M, Benedetti F, Campisi G, et al.Evolution patterns of SARS-CoV-2:Snapshot on its genome variants[J].Biochemical and Biophysical Research Communications, 2021, 538:88-91.
[6] Zawilska J B, Lagodzinski A, Berezinska M.COVID-19:From the structure and replication cycle of SARS-CoV-2 to its disease symptoms and treatment[J].Journal of Physiology And Pharmacology, 2021, 72(4):479-501.
[7] Jackson C B, Farzan M, Chen B, et al.Mechanisms of SARS-CoV-2 entry into cells[J].Nature Reviews Molecular Cell Biology, 2022, 23(1):3-20.
[8] Yang H, Rao Z.Structural biology of SARS-CoV-2 and implications for therapeutic development[J].Nature Reviews Microbiology, 2021, 19(11):685-700.
[9] Trougakos I P, Stamatelopoulos K, Terpos E, et al.Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications[J].Journal of Biomedical Science, 2021, 28(1):9.
[10] World Health Organization.Tracking SARS-CoV-2 variants[EB/OL].[2022-11-22].https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
[11] 杨婧荣, 桓瑜, 龚玉环, 等.2021年新冠病毒变异、跨种传播及疫苗和药物研究热点回眸[J].科技导报, 2022, 40(1):132-149.
[12] Park H, Park M S, Seok J H, et al.Insights into the immune responses of SARS-CoV-2 in relation to COVID-d:PDF.pdf19 vaccines[J].Journal of Microbiology, 2022, 60(3):308-320.
[13] 石云, 王宁, 邹全明.新型冠状病毒疫苗研发进展与挑战[J].中华预防医学杂志, 2020, 54(6):614-619.
[14] Sadoff J, Gray G, Vandebosch A, et al.Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19[J].New England Journal of Medicine, 2021, 384(23):2187-2201.
[15] Voysey M, Costa C S A, Madhi S A, et al.Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19(AZD1222) vaccine:a pooled analysis of four randomised trials[J].Lancet, 2021, 397(10277):881-891.
[16] Jones I, Roy P.Sputnik V COVID-19 vaccine candidate appears safe and effective[J].Lancet, 2021, 397(10275):642-643.
[17] Dunkle L M, Kotloff K L, Gay C L, et al.Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico[J].New England Journal of Medicine, 2022, 386(6):531-543.
[18] Thuluva S, Paradkar V, Gunneri S, et al.Safety, tolerability and immunogenicity of Biological E's CORBEVAX TM vaccine in children and adolescents:A prospective, randomised, double-blind, placebo controlled, phase-2/3 study[J].Vaccine, 2022, 40(49):7130-7140.
[19] Song J Y, Choi W S, Heo J Y, et al.Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03:A randomised, placebo-controlled, observer-blinded phase 1/2 trial[J].EClinicalMedicine, 2022, 51:101569.
[20] Polack F P, Thomas S J, Kitchin N, et al.Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine[J].New England Journal of Medicine, 2020, 383(27):2603-d:PDF.pdf2615.
[21] Teo S P.Review of COVID-19 mRNA vaccines:BNT162b2 and mRNA-1273[J].Journal of Pharmaceutical Sciences, 2022, 35(6):947-951.
[22] Al Kaabi N, Zhang Y, Xia S, et al.Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults:A randomized clinical trial[J].Jama, 2021, 326(1):35-45.
[23] Ranzani O T, Hitchings M D T, Dorion M, et al.Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of COVID-19 in Brazil:Test negative case-control study[J].British Medical Journal, 2021, 374:n2015.
[24] Zhu F, Jin P, Zhu T, et al.Safety and immunogenicity of a recombinant adenovirus type-5-vectored coronavirus disease 2019(COVID-19) vaccine with a homologous prime-boost regimen in healthy participants aged ≥ 6 years:A randomized, double-blind, placebo-controlled, phase 2b trial[J].Clinical Infectious Diseases, 2022, 75(1):783-791.
[25] Dai L, Gao L, Tao L, et al.Efficacy and safety of the RBD-dimer-based COVID-19 vaccine ZF2001 in adults[J].New England Journal of Medicine, 2022, 386(22):2097-2111.
[26] Andrews N, Stowe J, Kirsebom F, et al.COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant[J].New England Journal of Medicine, 2022, 386(16):1532-1546.
[27] Tartof S Y, Slezak J M, Puzniak L, et al.BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5[J].Lancet Infectious Diseases, 2022, 22(12):1663-1665.
[28] Scheaffer S M, Lee D, Whitener B, et al.Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice[J].Nature Medicine, 2023, 29:247-257.
[29] Clarivate Cortellis[EB/OL].[2022-11-22].https://access.cortellis.cn.
[30] Kumar A, Blum J, Thanh Le T, et al.The mRNA vaccine development landscape for infectious diseases[J].Nature Reviews Drug Discovery, 2022, 21(5):333-334.
[31] Ying B, Scheaffer S M, Whitener B, et al.Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice[J].Cell, 2022, 185(9):1572-1587.
[32] Kurhade C, Zou J, Xia H, et al.Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine[J].Nature Communications, 2022, 13(1):3602.
[33] Chen G L, Li X F, Dai X H, et al.Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults:A randomised, double-blind, placebocontrolled, phase 1 trial[J].Lancet Microbe, 2022, 3(3):193-202.
[34] Tan Y, Lu S, Wang B, et al.Single-cell transcriptome atlas reveals protective characteristics of COVID-19 mRNA vaccine[J].Journal of Medical Virology, doi:10.1002/jmv.28161.
[35] Pardi N, Hogan M J, Weissman D.Recent advances in mRNA vaccine technology[J].Current Opinion In Immunology, 2020, 65:14-20.
[36] Chaudhary N, Weissman D, Whitehead K A.mRNA vaccines for infectious diseases:Principles, delivery and clinical translation[J].Nature Reviews Drug Discovery, 2021, 20(11):817-838.
[37] Joyce M G, King H A D, Elakhal-Naouar I, et al.A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates[J].Science Translational Medicine, 2022, 14(632):eabi5735.
[38] Morens D M, Taubenberger J K, Fauci A S.Universal coronavirus vaccines-an urgent need[J].New England Journal of Medicine, 2022, 386(4):297-299.
[39] Faheem, Kumar B K, Sekhar K, et al.Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19[J].Bioorganic Chemistry, 2020, 104:104269.
[40] Liu X, Huuskonen S, Laitinen T, et al.SARS-CoV-2-d:PDF.pdfhost proteome interactions for antiviral drug discovery[J].Molecular Systems Biology, 2021, 17(11):e10396.
[41] Xiang R, Wang Y, Wang L, et al.Neutralizing monoclonal antibodies against highly pathogenic coronaviruses[J].Current Opinion In Virology, 2022, 53:101199.
[42] Hurt A C, Wheatley A K.Neutralizing antibody therapeutics for COVID-19[J].Viruses, 2021, 13(4):628.
[43] Barnes C O, Jette C A, Abernathy M E, et al.SARSCoV-2 neutralizing antibody structures inform therapeutic strategies[J].Nature, 2020, 588(7839):682-687.
[44] Xiaojie S, Yu L, Lei Y, et al.Neutralizing antibodies targeting SARS-CoV-2 spike protein[J].Stem Cell Research, 2020, 50:102125.
[45] Dougan M, Nirula A, Azizad M, et al.Bamlanivimab plus etesevimab in mild or moderate COVID-19[J].New England Journal of Medicine, 2021, 385(15):1382-d:PDF.pdf1392.
[46] Ganesh R, Philpot L M, Bierle D M, et al.Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019[J].Journal of Infectious Diseases, 2021, 224(8):1278-1286.
[47] Gupta A, Gonzalez-Rojas Y, Juarez E, et al.Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab[J].New England Journal of Medicine, 2021, 385(21):1941-1950.
[48] Ji Y, Zhang Q, Cheng L, et al.Preclinical characterization of amubarvimab and romlusevimab, a pair of noncompeting neutralizing monoclonal antibody cocktail, against SARS-CoV-2[J].Frontiers in Immunology, 2022, 13:980435.
[49] Westendorf K, Žentelis S, Wang L, et al.LY-CoV1404(bebtelovimab) potently neutralizes SARS-CoV-2 variants[J].bioRxiv, 2022, 39(7):110812.
[50] Cao Y, Wang J, Jian F, et al.Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies[J].Nature, 2022, 602(7898):657-663.
[51] Schmidt F, Muecksch F, Weisblum Y, et al.Plasma neutralization of the SARS-CoV-2 Omicron variant[J].New England Journal of Medicine, 2022, 386(6):599-601.
[52] Yuan M, Zhu X, He W T, et al.A broad and potent neutralization epitope in SARS-related coronaviruses[J].Proceedings of the National Academy of Sciences of the United States of America, 2022, 119(29):e2205784119.
[53] Sang L, Cheng B, Yu Y, et al.The efficacy and safety of IBI314 on delta and omicron variant of SARS-CoV-2:First-in-human evidence[J].Journal of Infection, 2022, 85(3):334-363.
[54] McCreary E K, Angus D C.Efficacy of remdesivir in COVID-19[J].JAMA, 2020, 324(11):1041-1042.
[55] Najjar-Debbiny R, Gronich N, Weber G, et al.Effectiveness of Paxlovid in reducing severe COVID-19 and Mortality in high risk patients[J].Clinical Infectious Diseases, 2022, doi:10.1093/cid/ciac443.
[56] Mahase E.COVID-19:Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports[J].British Medical Journal, 2021, 375:2422.
[57] Mukae H, Yotsuyanagi H, Ohmagari N, et al.A randomized phase 2/3 study of ensitrelvir, a novel oral SARSCoV-23C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection:Results of the phase 2a part[J].Antimicrob Agents Chemother, 2022, 66(10):e0069722.
[58] McCoy J, Goren A, Cadegiani F A, et al.Proxalutamide reduces the rate of hospitalization for COVID-19 male outpatients:A Randomized double-blinded placebo-controlled trial[J].Frontiers of Medicine (Lausanne), 2021, 8:668698.
[59] Shen Y, Ai J, Lin N, et al.An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants[J].Emerging Microbes & Infections, 2022, 11(1):1518-1523.
[60] Ren Z, Luo H, Yu Z, et al.A randomized, open-label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study[J].Advanced Science (Weinh), 2020, 7(19):e2001435.
